82 FR 10025 - Prospective Grant of Exclusive Patent License: Inhibition of Plasmodial Surface Anion Channels for the Treatment or Prevention of Malaria

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 26 (February 9, 2017)

Page Range		10025-10025
FR Document		2017-02673

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Commercialization Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Summary Information section of this notice to Microbiotix, Inc. (``Microbiotix'') located in Worcester, Massachusetts.

Federal Register, Volume 82 Issue 26 (Thursday, February 9, 2017)

[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)]
[Notices]
[Page 10025]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-02673]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Inhibition of 
Plasmodial Surface Anion Channels for the Treatment or Prevention of 
Malaria

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases, an 
institute of the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an Exclusive 
Commercialization Patent License to practice the inventions embodied in 
the Patents and Patent Applications listed in the Summary Information 
section of this notice to Microbiotix, Inc. (``Microbiotix'') located 
in Worcester, Massachusetts.

DATES: Only written comments and/or applications for a license which 
are received by the National Institute of Allergy and Infectious 
Diseases' Technology Transfer and Intellectual Property Office on or 
before February 24, 2017 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated Exclusive Commercialization 
Patent License should be directed to: Peter Tung, Technology Transfer 
and Patent Specialist, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Suite 6D, MSC9804, Rockville, MD 20852-9804 Telephone: 
(301) 496-2644; Facsimile: (240) 627-3117; Email: [email protected].

SUPPLEMENTARY INFORMATION:

Intellectual Property

    United States Provisional Patent Application No. 61/083,000, filed 
July 23, 2008 and entitled ``Inhibitors of the Plasmodial Surface Anion 
Channel as Antimalarials'' [HHS Reference No. E-202-2008/0-US-01]; PCT 
Patent Application PCT/US09/50637, filed July 15, 2009 and entitled 
``Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials'' 
[HHS Reference No. E-202-2008/0-PCT-02]; and U.S. and foreign patent 
applications claiming priority to the aforementioned applications.
    United States Provisional Patent Application No. 61/474,583, filed 
April 12, 2011 and entitled ``Plasmodial Surface Anion Channel 
Inhibitors for the Treatment of Malaria'' [HHS Reference No. E-145-
2011/0-US-01]; PCT Patent Application PCT/US12/33072, filed April 11, 
2012 and entitled ``Plasmodial Surface Anion Channel Inhibitors for the 
Treatment of Malaria'' [HHS Reference No. E-202-2008/0-PCT-02]; and 
U.S. and foreign patent applications claiming priority to the 
aforementioned applications.
    The patent rights in these inventions have been assigned to the 
government of the United States of America.
    The prospective exclusive license territory may be worldwide and 
the field of use may be limited to: ``Methods of preventing and/or 
treating malaria infection by inhibition of Plasmodium Surface Anion 
Channels (PSAC) with anti-PSAC compounds.''
    This technology discloses a novel anion channel on the surface of 
red blood cells (RBCs) in animals infected with Plasmodium. Named PSAC 
for ``plasmodium surface anion channel,'' this channel protein 
facilitates the transport of nutrients into RBCs for the plasmodium 
parasite. Sugars, amino acids, purines, vitamins, and precursors for 
phospholipid biosynthesis have markedly increased uptake into infected 
RBCs via PSAC. Many of these nutrients have negligible uptake in 
uninfected RBCs. PSACs, which allow nutrients to reach the growing 
plasmodium parasites inside RBCs, therefore serves as a new target for 
the development of antimalarial compounds. The disclosed anti-PSAC 
compositions and methods of using these anti-PSAC compounds provide a 
means for prevention or treatment of malaria infection by blocking 
nutrients to plasmodium parasites.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Institute of Allergy and Infectious Diseases receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 
404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Exclusive Commercialization Patent 
License Agreement. Comments and objections submitted to this notice 
will not be made available for public inspection and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

    Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-02673 Filed 2-8-17; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices 10025

Dated: February 6, 2017. foreign patent applications claiming Commercialization Patent License
Natasha M. Copeland, priority to the aforementioned Agreement. Comments and objections
Program Analyst, Office of Federal Advisory applications. submitted to this notice will not be
Committee Policy. United States Provisional Patent made available for public inspection
[FR Doc. 2017–02727 Filed 2–8–17; 8:45 am] Application No. 61/474,583, filed April and, to the extent permitted by law, will
BILLING CODE 4140–01–P 12, 2011 and entitled ‘‘Plasmodial not be released under the Freedom of
Surface Anion Channel Inhibitors for Information Act, 5 U.S.C. 552.
the Treatment of Malaria’’ [HHS Dated: February 6, 2017.
DEPARTMENT OF HEALTH AND Reference No. E–145–2011/0–US–01];
Suzanne Frisbie,
HUMAN SERVICES PCT Patent Application PCT/US12/
33072, filed April 11, 2012 and entitled Deputy Director, Technology Transfer and
National Institutes of Health Intellectual Property Office, National Institute
‘‘Plasmodial Surface Anion Channel
of Allergy and Infectious Diseases.
Inhibitors for the Treatment of Malaria’’
Prospective Grant of Exclusive Patent [FR Doc. 2017–02673 Filed 2–8–17; 8:45 am]
[HHS Reference No. E–202–2008/0–
License: Inhibition of Plasmodial PCT–02]; and U.S. and foreign patent BILLING CODE 4140–01–P
Surface Anion Channels for the applications claiming priority to the
Treatment or Prevention of Malaria aforementioned applications.
The patent rights in these inventions DEPARTMENT OF THE INTERIOR
AGENCY: National Institutes of Health,
HHS. have been assigned to the government of
the United States of America. Geological Survey
ACTION: Notice. The prospective exclusive license [17 GX17CJ00GKC0100]
SUMMARY: The National Institute of territory may be worldwide and the
Allergy and Infectious Diseases, an field of use may be limited to: ‘‘Methods Notice of an Open Meeting of the
institute of the National Institutes of of preventing and/or treating malaria Advisory Committee on Water
Health, Department of Health and infection by inhibition of Plasmodium Information
Human Services, is contemplating the Surface Anion Channels (PSAC) with
anti-PSAC compounds.’’ AGENCY: United States Geological
grant of an Exclusive Commercialization Survey, Department of the Interior.
Patent License to practice the inventions This technology discloses a novel
embodied in the Patents and Patent anion channel on the surface of red ACTION: Notice of an open meeting of the
Applications listed in the Summary blood cells (RBCs) in animals infected Advisory Committee on Water
Information section of this notice to with Plasmodium. Named PSAC for Information (ACWI).
Microbiotix, Inc. (‘‘Microbiotix’’) ‘‘plasmodium surface anion channel,’’
this channel protein facilitates the SUMMARY: Notice is hereby given of a
located in Worcester, Massachusetts. meeting of the ACWI. This meeting is to
transport of nutrients into RBCs for the
DATES: Only written comments and/or discuss broad policy-related topics
plasmodium parasite. Sugars, amino
applications for a license which are acids, purines, vitamins, and precursors relating to national water initiatives,
received by the National Institute of for phospholipid biosynthesis have and the development and dissemination
Allergy and Infectious Diseases’ markedly increased uptake into infected of water information, through reports
Technology Transfer and Intellectual RBCs via PSAC. Many of these nutrients from ACWI subgroups. The agenda will
Property Office on or before February have negligible uptake in uninfected include updates from ACWI’s various
24, 2017 will be considered. RBCs. PSACs, which allow nutrients to subcommittees, unveiling of the
ADDRESSES: Requests for copies of the reach the growing plasmodium parasites strategic plan for the Water Quality
patent application, inquiries, and inside RBCs, therefore serves as a new Portal for 2017–2021, a proposal for a
comments relating to the contemplated target for the development of new Terms of Reference document for
Exclusive Commercialization Patent antimalarial compounds. The disclosed the Subcommittee on Ground Water, a
License should be directed to: Peter anti-PSAC compositions and methods of proposal to establish a new Risk
Tung, Technology Transfer and Patent using these anti-PSAC compounds Management Workgroup within the
Specialist, Technology Transfer and provide a means for prevention or Subcommittee on Hydrology, an update
Intellectual Property Office, National treatment of malaria infection by on activities and accomplishments
Institute of Allergy and Infectious blocking nutrients to plasmodium related to the Open Water Data
Diseases, 5601 Fishers Lane, Suite 6D, parasites. Initiative, and a report on the
MSC9804, Rockville, MD 20852–9804 This notice is made in accordance Hydrologic Frequency Analysis Work
Telephone: (301) 496–2644; Facsimile: with 35 U.S.C. 209 and 37 CFR part 404. Group’s progress on Bulletin 17C,
(240) 627–3117; Email: peter.tung@ The prospective exclusive license will Guidelines For Determining Flood Flow
nih.gov. be royalty bearing, and the prospective Frequency.
SUPPLEMENTARY INFORMATION: exclusive license may be granted unless The ACWI was established under the
within fifteen (15) days from the date of authority of the Office of Management
Intellectual Property this published notice, the National and Budget Memorandum M–92–01 and
United States Provisional Patent Institute of Allergy and Infectious the Federal Advisory Committee Act.
Application No. 61/083,000, filed July Diseases receives written evidence and The purpose of the ACWI is to provide
23, 2008 and entitled ‘‘Inhibitors of the argument that establishes that the grant a forum for water information users and
Plasmodial Surface Anion Channel as professionals to advise the Federal
sradovich on DSK3GMQ082PROD with NOTICES

of the license would not be consistent
Antimalarials’’ [HHS Reference No. E– with the requirements of 35 U.S.C. 209 Government on activities and plans that
202–2008/0–US–01]; PCT Patent and 37 CFR part 404. may improve the effectiveness of
Application PCT/US09/50637, filed July Complete applications for a license in meeting the Nation’s water information
15, 2009 and entitled ‘‘Inhibitors of the the prospective field of use that are filed needs. Member organizations help to
Plasmodial Surface Anion Channel as in response to this notice will be treated foster communications between the
Antimalarials’’ [HHS Reference No. E– as objections to the grant of the Federal and non-Federal sectors on
202–2008/0–PCT–02]; and U.S. and contemplated Exclusive sharing water information.

VerDate Sep<11>2014 18:11 Feb 08, 2017 Jkt 241001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\09FEN1.SGM 09FEN1

Document Created: 2017-02-09 01:02:39
Document Modified: 2017-02-09 01:02:39

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before February 24, 2017 will be considered.
FR Citation		82 FR 10025

82 FR 10025 - Prospective Grant of Exclusive Patent License: Inhibition of Plasmodial Surface Anion Channels for the Treatment or Prevention of Malaria

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 82, Issue 26 (February 9, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health